Sensus Healthcare Records Over 150% Jump In Q4 Sales


Sensus Healthcare Inc's SRTS Q4 FY21 sales increased 156% to $13 million, primarily driven by a higher number of units sold as the market continued to reopen, beating the consensus of $11.7 million.

  • The gross profit margin improved to 68% of revenues, compared with $3.2 million, or 63.4% of revenues.
  • The Company shipped a record 35 systems, including three SRT-100 systems, to China.
  • "Record revenues for the fourth quarter were significantly higher than for any quarter in the company's history," said Joe Sardano, Chairman & CEO. 
  • "We are comfortable that this momentum will continue through 2022 as so many of our initiatives are being very well-executed.
  • "We were delighted to receive a license renewal from China's Ministry of Health to market the SRT-100 system. This new license runs through December 2026 and covers the sale of our superficial radiation therapy to treat non-melanoma skin cancer and keloids," added Joe Sardano.
  • The Company reported Q4 EPS of $0.32 compared to $0.06 a year ago, surpassing the consensus of $0.15.
  • Adjusted EBITDA was $5.6 million, compared with $1.3 million for the fourth quarter of 2020. 
  • Cash and investments were $14.5 million.
  • Price Action: SRTS shares are trading 3.12% higher at $8.11 during market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!